Tanshinones increase fibrinolysis through inhibition of plasminogen activator inhibitor-1.
作者信息
Xiao Ying-Hong, Yang Long-Fei, Feng Xue-Chao, Yang Hong, Ma Tong-Hui
出版信息
CNS Neurosci Ther. 2012 May;18(5):436-8. doi: 10.1111/j.1755-5949.2012.00307.x.
Abstract
摘要
相似文献
1
Tanshinones increase fibrinolysis through inhibition of plasminogen activator inhibitor-1.
CNS Neurosci Ther. 2012 May;18(5):436-8. doi: 10.1111/j.1755-5949.2012.00307.x.
2
Interaction of fucoidan with proteases and inhibitors of coagulation and fibrinolysis.岩藻依聚糖与蛋白酶以及凝血和纤维蛋白溶解抑制剂的相互作用。
Thromb Res. 1997 Sep 1;87(5):419-29. doi: 10.1016/s0049-3848(97)00158-8.
3
Bispecific monoclonal antibodies increase the fibrin-specific fibrinolytic activity of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA).
Ann N Y Acad Sci. 1992 Dec 4;667:428-30. doi: 10.1111/j.1749-6632.1992.tb51644.x.
4
Regulation of intrapleural fibrinolysis by urokinase-alpha-macroglobulin complexes in tetracycline-induced pleural injury in rabbits.尿激酶-α-巨球蛋白复合物对四环素诱导的兔胸膜损伤中胸膜内纤维蛋白溶解的调节作用
Am J Physiol Lung Cell Mol Physiol. 2009 Oct;297(4):L568-77. doi: 10.1152/ajplung.00066.2009. Epub 2009 Aug 7.
5
Inhibition of plasminogen activator inhibitor-1 activity by two diketopiperazines, XR330 and XR334 produced by Streptomyces sp.链霉菌属产生的两种二酮哌嗪XR330和XR334对纤溶酶原激活物抑制剂-1活性的抑制作用
J Antibiot (Tokyo). 1996 Oct;49(10):1014-21. doi: 10.7164/antibiotics.49.1014.
6
A specific plasminogen activator inhibitor-1 antagonist derived from inactivated urokinase.一种源自灭活尿激酶的特异性纤溶酶原激活物抑制剂-1拮抗剂。
J Cell Mol Med. 2016 Oct;20(10):1851-60. doi: 10.1111/jcmm.12875. Epub 2016 May 20.
7
Inhibition of Borrelia burgdorferi-bound fibrinolytic enzymes by alpha2-antiplasmin, PAI-1 and PAI-2.α2-抗纤溶酶、纤溶酶原激活物抑制剂-1（PAI-1）和纤溶酶原激活物抑制剂-2（PAI-2）对伯氏疏螺旋体结合的纤溶酶的抑制作用。
Biochem Biophys Res Commun. 1996 Feb 27;219(3):690-5. doi: 10.1006/bbrc.1996.0296.
8
Fibrin-specific fibrinolysis.纤维蛋白特异性纤溶
Ann N Y Acad Sci. 1992 Dec 4;667:259-71. doi: 10.1111/j.1749-6632.1992.tb51623.x.
9
Plasminogen activator inhibitor-1.纤溶酶原激活物抑制剂-1
Curr Med Chem. 2004 Sep;11(17):2323-34. doi: 10.2174/0929867043364595.
引用本文的文献
1
Plasminogen Activator Inhibitors in Thrombosis: Structural Analysis and Potential Natural Inhibitors.血栓形成中的纤溶酶原激活物抑制剂：结构分析与潜在的天然抑制剂
ACS Omega. 2025 Jun 19;10(25):27348-27362. doi: 10.1021/acsomega.5c02926. eCollection 2025 Jul 1.
2
Proteins and DNA Sequences Interacting with Tanshinones and Tanshinone Derivatives.与丹参酮及丹参酮衍生物相互作用的蛋白质和DNA序列
Int J Mol Sci. 2025 Jan 20;26(2):848. doi: 10.3390/ijms26020848.
3
Role and molecular mechanism of Salvia miltiorrhiza associated with chemical compounds in the treatment of diabetes mellitus and its complications: A review.丹参相关化学化合物治疗糖尿病及其并发症的作用和分子机制：综述。
Medicine (Baltimore). 2024 Apr 19;103(16):e37844. doi: 10.1097/MD.0000000000037844.
4
Effects of tanshinone combined with valsartan on hypertensive nephropathy and its influence on renal function and vascular endothelial function.丹参酮联合缬沙坦对高血压肾病的影响及其对肾功能和血管内皮功能的作用
Am J Transl Res. 2021 May 15;13(5):4788-4795. eCollection 2021.
5
Bioactivity-Guided Fractionation of the Traditional Chinese Medicine Resina Draconis Reveals Loureirin B as a PAI-1 Inhibitor.中药血竭的生物活性导向分离揭示龙血素B为PAI-1抑制剂。
Evid Based Complement Alternat Med. 2017;2017:9425963. doi: 10.1155/2017/9425963. Epub 2017 Sep 18.
6
Inhibition of PAI-1 Activity by Toddalolactone as a Mechanism for Promoting Blood Circulation and Removing Stasis by Chinese Herb var. .以滨蒿内酯抑制纤溶酶原激活物抑制剂-1活性作为中药促进血液循环、祛瘀的作用机制。
Front Pharmacol. 2017 Jul 21;8:489. doi: 10.3389/fphar.2017.00489. eCollection 2017.
本文引用的文献
1
PAI-1 in tissue fibrosis.组织纤维化中的 PAI-1。
J Cell Physiol. 2012 Feb;227(2):493-507. doi: 10.1002/jcp.22783.
2
Therapeutic potential of plasminogen activator inhibitor-1 inhibitors.纤溶酶原激活物抑制剂-1抑制剂的治疗潜力。
Ther Adv Cardiovasc Dis. 2010 Oct;4(5):315-24. doi: 10.1177/1753944710379126. Epub 2010 Jul 26.
3
A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates.一种新型纤溶酶原激活物抑制剂-1 抑制剂在非人类灵长类动物中具有抗血栓作用而无出血效应。
J Cereb Blood Flow Metab. 2010 May;30(5):904-12. doi: 10.1038/jcbfm.2009.272. Epub 2010 Jan 20.
4
Plasminogen activator inhibitor-1 and the circadian clock in metabolic disorders.纤溶酶原激活物抑制剂-1与代谢紊乱中的生物钟
Clin Exp Hypertens. 2009 May;31(3):208-19. doi: 10.1080/10641960902822468.
5
The effects of pharmacological PAI-1 inhibition on thrombus formation and neointima formation after arterial injury.药理学抑制纤溶酶原激活物抑制剂-1对动脉损伤后血栓形成和新生内膜形成的影响。
Expert Opin Ther Targets. 2008 Jul;12(7):783-94. doi: 10.1517/14728222.12.7.783.
6
Fibrinolysis: the key to new pathogenetic mechanisms.纤维蛋白溶解：新发病机制的关键。
Curr Med Chem. 2008;15(9):923-9. doi: 10.2174/092986708783955455.
7
Plasminogen activator inhibitor-1 in vascular thrombosis.血管血栓形成中的纤溶酶原激活物抑制剂-1
Curr Drug Targets. 2007 Sep;8(9):966-1002. doi: 10.2174/138945007781662328.
8
Preclinical and clinical examinations of Salvia miltiorrhiza and its tanshinones in ischemic conditions.丹参及其丹参酮在缺血条件下的临床前和临床研究。
Chin Med. 2006 Nov 23;1:3. doi: 10.1186/1749-8546-1-3.
9
Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use.丹参：其化学、药理学、药代动力学及临床应用概述
J Clin Pharmacol. 2005 Dec;45(12):1345-59. doi: 10.1177/0091270005282630.
10
In vitro Radix salviae miltiorrhizae action on blood anticoagulation and fibrinogenolysis.丹参在体外的血液抗凝及纤维蛋白溶解作用。
Chin Med J (Engl). 1978 Mar;4(2):123-6.
Zotero 插件